Cancer Biotech's Upsized $238M IPO Leads Three Deals
Venture-backed oncology firm Revolution Medicines Inc. saw its shares soar upon their debut Thursday after raising $238 million in an upsized initial public offering, sealing the largest deal among three newly...To view the full article, register now.
Already a subscriber? Click here to view full article